Could a targeted drug beat standard care for shock in liver patients?

NCT ID NCT07568275

Ongoing Disease control Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a drug called Angiotensin II can raise blood pressure more effectively than standard medications in people with liver cirrhosis who have septic shock. Researchers will measure how well the heart and blood vessels work together over 24 hours. The trial involves 30 participants and is in an early phase, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Angiotensin II (Giapreza)
What this could lead to: If it works, this could point toward a better way to manage dangerous low blood pressure in people with liver disease and sepsis.
What could go wrong: This is a very early, small study with only 30 participants, so results may not apply broadly. The drug may not work better than current treatments and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury cirrhosis of liver Fibrosis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY CIRRHOSIS SEPTIC SHOCK VASODILATORY SHOCK

Contacts and locations

Locations

The Cleveland Clinic

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.